Proposal and protocol for the construction of pEF1-ACE2-IGG2-SMAR vector for gene therapy of SARS-CoV-2
Description
The Coronavirus SARS-CoV-2, the etiological agent of COVID-19. Utilizes cellular ACE2 receptors for the entry of cells. This receptor binds to the receptor binding motif(RBM) of the SARS-CoV-2 S protein with affinity of around 100nM—comparable to a very high affinity monoclonal antibody. Fusion proteins consisting of the ectodomain of ACE2 fused to the Fc region of a human Antibody have been proven to neutralize the SARS-CoV-2 virus in vitro[1][2], and displayed extended serum half-life and lack of toxicity in-vivo[1][2][3]. In addition, this fusion protein have been proven to significantly attenuate SARS-CoV-2 infection In-Vivo using a murine model[1]. Such recombinant proteins have been proposed as a form of therapeutic for COVID-19 patients.
Files
pEF_Episomal_Vector_ACE2_IGG2_K326W_E333S_oligos.txt
Files
(878.5 kB)
Name | Size | Download all |
---|---|---|
md5:2c1f196791048182cf562906e56ea179
|
10.7 kB | Download |
md5:0e680f9dcb9a744d8cc311aece83b943
|
11.4 kB | Download |
md5:b801a5ae897afdf32fbe0d839286295d
|
30.6 kB | Download |
md5:276d63a8a9cfb11a27d4571c90144041
|
22.9 kB | Download |
md5:4c9fb03f5a51246bde5230b3db625965
|
16.1 kB | Download |
md5:c197499770f22e7ee2b7a76adae75a20
|
9.6 kB | Download |
md5:f8354523ff15d00c45b3ff659eabfa18
|
494 Bytes | Preview Download |
md5:e5fe1794992558d9858db3116ccde6a3
|
91.8 kB | Preview Download |
md5:3598e4e56f377b6ec665a529d10c4264
|
683.4 kB | Preview Download |
md5:2caed5a91f5bf6b8c2a246622bdafb74
|
1.6 kB | Preview Download |